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Abstract
The overall goal of this research is to develop a minimally invasive glucose
sensing system for diabetic patients. The device will consist of an array of micro-needles
that penetrates only the stratum corneum layer of the skin and tests glucose levels in the
interstitial fluid (IF). This device does not reach the depth of the nerve endings, and so
provides a painless means of glucose measurement. Glucose will be detected
amperometrically using a two step chemical process in which glucose is broken down
into hydrogen peroxide which is then oxidized to provide a current. By coating the outer
surface of the micro-needle array with layers of rhodium, cellulose acetate, and glucose
acetate using electrochemical deposition, the needles can be sensitized to the presence of
glucose.
Successful work has been completed in which needle surfaces were sensitized to
glucose by layering the reaction catalyst (glucose oxidase) and cellulose acetate onto
rhodium coated 0.51 mm diameter stainless steel wires. This was achieved through a
combination of galvanostatic depositions and dip coatings. These sensors were able to
detect various concentrations of glucose within the biological range (0-20 mM). Micro-
needles arrays have been fabricated from stainless steel and coated with rhodium in order
to sensitize the surface to hydrogen peroxide. The array design increases the probability
that the micro-needles will reach the IF rather than become embedded in the surrounding
epithelial cells. The array design also increases the sensor surface area, thus yielding
higher amperometric response signals. Other benefits of microelectrodes such as faster
response times, higher signal to noise ratios, and lower sensitivity to convection are
amplified when micro-needles are used in an array format. Future work on this device
will be to integrate the glucose sensor with the array design to create a microneedle array
that can effectively measure glucose levels in IF.
Thesis Supervisor: Lynette Jones
Title: Principle Research Scientist
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Chapter One: Introduction
The overall goal of this research is to develop a minimally invasive miniature
device for diabetic patients that controls the delivery of insulin using feedback from an
integrated glucose sensor. This system will incorporate a micro-needle array to measure
glucose levels in the interstitial fluid (IF) rather than in the blood, because IF, which lies
below the outer layer of the skin, can be sampled relatively painlessly and directly from
the dermis. The device must be able to measure glucose levels accurately and dispense
the appropriate amount of insulin, using the glucose measurement as feedback in the
control loop. In its final form, the device must also be easily miniaturizable and able to
be mass-produced.
Although many commercial entities are working towards the development of similar
technology, no one as yet has been able to create a closed-loop system that can
adequately measure the dynamic human response to glucose levels following the
injection of insulin. All devices on the market currently are open-loop systems which
either record only current glucose levels or deliver bolus amounts of insulin at pre-
programmed times. The most notable recent development in this area came on June 15,
1999 when the U.S. Food and Drug Administration (FDA) approved the application for
MiniMed's continuous glucose monitoring system [MiniMed, 1999]. This system is able
to monitor continuously glucose for up to three days using an electrode inserted under the
patient's skin. However, patients are still required to perform conventional fingerprick
blood glucose tests at least four times a day for calibration purposes.
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Although the MiniMed sensor is indeed progress towards the goal of a closed-loop
monitoring system, it has not yet solved many of the issues involved in glucose
measurement, such as the elimination of invasive and painful blood glucose testing, the
integration of insulin delivery with glucose sensing, and a characterization of the
dynamic human response to glucose and insulin fluctuations. The ultimate goal of the
present research is to address all of these issues. The array of glucose-sensitive micro-
needles is designed to measure glucose from the IF without contacting nerve fibers and so
creates a minimally invasive and painless method of glucose testing. By using system
identification techniques, the dynamic human response to insulin injections can be
characterized. Knowledge of the diabetic impulse response function will allow
application of a predictive model to insulin delivery. The glucose sensor/insulin delivery
system will anticipate glucose level increases much as the human pancreas does in non-
diabetic patients. System identification techniques will also be applied to determine the
sensor response to glucose injections in a diffusive medium. When combined with an
integrated pump that delivers glucose proximal to the sensor, this information may be
used to calibrate the sensor in situ.
This thesis describes the initial work that has been done on the development of a
minimally invasive glucose sensing system. It also discusses current products and
research in the field of minimally invasive closed-loop glucose detection and insulin
delivery.
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Chapter Two: Diabetes Overview
2.1 Diabetes Defined
Diabetes mellitus, often referred to simply as "diabetes," is a disease which
affects people of all ages and backgrounds. It may cause severe disability and even death
to those who do not receive adequate treatment. It is estimated that 15.7 million people
in the United States today are diabetic with approximately 800,000 new cases diagnosed
each year [American Diabetes Association (ADA), 1999a]. It is also estimated that 5.4
million of these people are unaware that they have the disease. Diabetes mellitus is listed
as the seventh leading cause of death in the United States, and there is no cure.
Complications that can arise from diabetes mellitus include retinopathy, kidney disease,
neuropathy, heart disease, and stroke. Total healthcare costs have been estimated at over
$98 billion per year [ADA, 1999a]. Approximately 20% of diabetics are completely
dependent on insulin therapy to control their diabetes. The other 80% are able to control
their diabetes through a program that includes dietary control and exercise. These
patients may have little or no need for supplementary insulin therapy [Rifkin and
Bernstein, 1988].
Diabetes mellitus is difficult to define as it is a combination of symptoms which
together make up what is seen as a disease. Basically, diabetes mellitus is a disorder of
carbohydrate metabolism characterized by hyperglycemia (high blood sugar) and
glycosuria (discharge of glucose in the urine) which results from inadequate production
or utilization of insulin. An operational definition was developed in 1979 by the National
Diabetes Data Group and accepted by the World Health Authority in 1980. They define
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diabetes mellitus as a condition where the venous plasma glucose level is greater than or
equal to 8 mM after fasting for at least 8 hours and/or greater than or equal to 11 mM two
hours after an ingestion of 75 g of glucose. In healthy people, the hormone insulin aids in
the absorption of glucose by the body's cells. Diabetics, however, lack normal insulin
activity, and thus are unable to regulate this flow of glucose into cells properly [Crabbe,
1987]. Diabetes mellitus occurs in various forms; 90% of the cases of diabetes mellitus
are classified as "spontaneous diabetes" and are further divided into two categories: Type
l and Type 2.
2.1.1 Type 1 Diabetes Meilitus
Type 1 diabetes mellitus is an autoimmune disease characterized by damage to the
pancreas and the destruction of pancreatic B cells. People with Type 1 diabetes mellitus
are unable to synthesize or secrete any insulin and must therefore take daily insulin
injections in order to stay alive. This type of diabetes is found most often in children and
young adults and accounts for 5-10 % of diabetics. It is often referred to as insulin-
dependent diabetes mellitus (IDDM). Current evidence suggests that IDDM may be a
genetically determined disorder as patients with IDDM show an increased frequency of
some histocompatiability antigens [Espinal, 1989]. These antigens are glycoproteins
found in the cell surface of all cells and are responsible for non-self recognition. IDDM
may also involve other autoimmune processes, as certain autoimmune disorders such as
Graves' disease, myasthenia gravis, pernicious anemia, and Addison's disease have long
been associated with IDDM patients. Environmental factors such as viruses may also be
a cause for IDDM. Congenital rubella occurs with a high frequency in patients who later
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develop IDDM. Other viruses such as Coxsackie virus B4 have also been reported to
induce IDDM in humans and mice [Espinal, 1989].
2.1.2 Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a metabolic disorder that decreases the body's ability
to produce enough insulin or to use the insulin that is produced properly. This type of
diabetes accounts for 90-95 % of spontaneous diabetics and is often found in the obese
and the elderly. People with Type 2 diabetes mellitus are sometimes able to control their
condition through diet and exercise; however, these people often have to resort to oral
medications or insulin injections to keep their glucose levels within an acceptable range
[Rifkin and Bernstein, 1988]. Type 2 diabetes is also referred to as non-insulin-
dependent diabetes mellitus (NIDDM); 90% of NIDDM patients have relatives with the
disease, however a genetic component of NIDDM is not as evident as with IDDM.
NIDDM is not associated with the histocompatiability antigens identified in people with
IDDM. There is, however, a much stronger association of the disease with environmental
factors such as age, diet, exercise, and psychosocial stress. NIDDM patients appear to be
insulin resistant. The cause for this resistance could include a defect or mutation in the
insulin gene, excess production of proinsulin instead of insulin, the presence of antibodies
to insulin and its receptor, and a defect in the mechanism of insulin action on its target
cells [Espinal, 1989]. Recent progress in the Human Genome Project has suggested that
a major gene for NIDDM may lie on Chromosome 20, indicating a possible DNA
mutation related to this disease [NHGRI, 1999].
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2.1.3 Other Forms of Diabetes Mellitus
There are various other forms of diabetes mellitus. The main categories of these
are secondary diabetes, impaired glucose tolerance, and gestational diabetes. Secondary
diabetes is defmed as a disease that is caused by an insult to the pancreas, drug treatment,
excess counter-regulatory hormones, or genetic hyperglycemia. Patients with impaired
glucose tolerance have normal fasting plasma glucose levels but very high glucose levels
following glucose ingestion. Gestational diabetes is a temporary form of diabetes
mellitus found in some pregnant women. This condition often reverses itself after the
woman has given birth, but it does put these women at a higher risk for developing Type
2 diabetes mellitus later in life [Espinal, 1989].
2.2 The Clinical Perspective
Two major studies have been carried out to address how diabetics can best control
their glucose and insulin levels so that they remain within a normal range. One such
study was carried out in the United Kingdom (UK) beginning in 1977. It is referred to as
the UK Prospective Diabetes Study (UKPDS) and was designed to determine whether
Type 2 diabetics would have a reduced risk of macrovascular and microvascular
complications, including stroke, heart failure, angina, renal failure, amputation, and
death, if they maintained intensive control of their blood glucose levels. The UKPDS
followed 5,102 patients over the course of 10 years. These patients were divided into two
groups, one using conventional diabetes therapy and the other using a more intensive
approach. Conventional therapy was defined as one or two insulin injections per day
(Figure 2.1), while the intensive therapy regimen attempted to keep patient blood glucose
13
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Figure 2. 1: Comparison of average nondiabetic blood glucose levels with
those of a diabetic patient under conventional insulin injection therapy over
the course of a day. Insulin injections were given to the diabetic patient
at hours 19 and 42 [Data from Weinless, 1986].
The conventional group also used methods of dietary control where necessary to maintain
glucose levels below 15 mM. The intensive group was encouraged to do regular home-
glucose monitoring in order to maintain glucose levels below 6 mM. The UKPDS
showed that there was a decrease in the frequency of many clinical complications in Type
2 diabetics who followed an intensive blood glucose control regimen. However, it also
found that intensive control tended to lead to an increased risk of hypoglycemic episodes
(low blood sugar caused by too large an insulin dosage) and greater weight gain
[UKPDS, 1998].
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The second major study, the Diabetes Control and Complications Trial (DCCT),
was started in 1983 in the United States. This study followed 1,441 patients with IDDM
over an average span of 6.5 years [DCCT, 1993]. It was designed as a multicenter,
randomized clinical trial whose purpose was to compare conventional diabetes mellitus
therapy with a more intensive approach. Patients using intensive therapy adjusted their
insulin dosages according to the results of blood glucose tests performed a minimum of
four times a day. These patients also accounted for dietary intake and anticipated
exercise in their dosages. The development of diabetic retinopathy in patients was used
as the central measure in the study, however the development of renal, neurological,
cardiovascular, and neuropsychological complications was also recorded, along with
other adverse effects directly related to the treatment regimens [DCCT, 1993].
The results of this study showed that intensive therapy delayed the onset and
slowed the progression of retinopathy by 35-70%. Intensive therapy was also shown to
reduce the risk of other microvascular and neurologic complications. Although, intensive
therapy did increase the risk of severe hypoglycemia, most patients were able to deal with
the hypoglycemic episodes themselves through sugar pills or other sugar intakes, and the
overall health benefits seemed to outweigh this risk. It was also suggested that tight
control of intensive therapy should help to reduce the occurrence of such episodes
[DCCT, 1993].
Based on the results of these two studies, most physicians now agree that both
Type 1 and Type 2 diabetics should maintain tighter control of their blood glucose levels
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through a more aggressive monitoring program. The goal of diabetics should be to
maintain their blood glucose levels as close to the normal levels as possible throughout
the day. This means maintaining preprandial (before meal) levels between 4.40-6.66 mM
(80 and 120 mg/dl) and bedtime levels between 5.55-7.77 mM (100 and 140 mg/dl)
[ADA, 1999b]. In order to accomplish this, it is suggested that patients test their glucose
levels a minimum of four times per day and adjust their daily routines, through diet,
exercise, and/or insulin injections, based on these readings.
2.3 Insulin Therapy
Insulin is a hormone and protein produced by the beta cells in the pancreas. It is
essential for the proper metabolizing of blood sugar (glucose) and for the maintenance of
proper blood sugar levels. For people who do not produce enough insulin or do not use
the insulin they do produce properly, additional insulin must be added to their systems.
Since insulin is a protein that breaks down during digestion, it cannot be ingested in the
form of a pill or oral medication. As such, insulin must be injected in order to properly
work its way into the blood. Using various methods, including a scintillation camera, to
monitor the distribution of injected insulin throughout the body, it has been shown that
insulin enters the blood stream at different rates when injected at different body sites.
Areas around joints and large nerve clusters have been found to be less effective in
delivering the insulin, whereas fast delivery is achieved when insulin is injected into the
abdomen. The upper arms, thighs, and buttocks are also acceptable injection areas
[ADA, 1997; Galloway and deShanzo, 1990; Schwartz, 1989].
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There are approximately thirty different types of insulin currently sold
commercially in the United States. These come from the pancreas of pigs and cows or
may be synthetically produced. Synthetic processes include the use of recombinant DNA
technology involving E. coli or the conversion of porcine to human insulin [Heine, 1988].
Each of these insulin types can be made in a variety of forms, characterized by how long
it takes for the insulin to begin working (onset), when the insulin is working the most
effectively (peak time), and how long the insulin remains in the body (duration). The
insulin types are generally classified as rapid-acting (Lispro), short-acting (Regular),
intermediate-acting (Lente), and long-acting (Ultralente). Rapid-acting insulin reaches
the bloodstream in about fifteen minutes, peaks one hour after injection, and remains in
the blood for two to four hours [Galloway and deShanzo, 1990; Strowig and Raskin,
1990]. Short-acting insulin can reach the blood within thirty minutes from the time of
injection, peaks two to three hours later, and stays in the blood for three to six hours.
Intermediate-acting insulin has an onset of two to four hours after injection, peaks four to
twelve hours later, and remains in the blood for ten to eighteen hours. Long-acting
insulin has an onset of six to ten hours from injection time, has a small peak (if any)
fourteen to twenty hours after injection, and remains in the blood for eighteen to twenty
hours [Galloway and deShanzo, 1990; Strowig and Raskin, 1990].
Lispro is the newest insulin analog on the market. Due to its fast onset and peak
times, it offers a more convenient and flexible approach to insulin therapy for patients.
Lispro can be administered immediately before meals, and patients do not need to wait a
specified time before eating or schedule specific meals around the injection time. Insulin
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therapy varies from patient to patient, and many people mix these different types of
insulin at different times during the day [ADA, 1998; Galloway and deShanzo, 1990;
Strowig and Raskin, 1990].
The site of injection also plays a role in insulin absorption. Insulin enters the
blood fastest when delivered in the abdomen, and more slowly from areas such as the
upper arms, thighs, and buttocks. However, repeated injections into the same area can
lead to tissue scarring which then impedes insulin absorption. It is therefore
recommended to rotate the site for injections around the region of choice. Conventional
insulin therapy is defined as taking the same volume of insulin injections at the same time
each day, usually twice a day. Intensive therapy entails three to four injections daily or
the use of an insulin pump. The timing of injections is usually based upon the results of
self monitoring of blood glucose levels to discover how long after an injection the insulin
begins to lower glucose levels. The goal is to time injections such that the insulin begins
to work at the same time the glucose from food begins to enter the bloodstream [DCCT,
1993; Schwartz, 1989].
The amount of insulin needed to maintain normal glucose levels is on the order of
0.02 to 0.03 mg per kilogram of body weight each day [Schwartz, 1989]. It is common to
refer to insulin in "units" where a single unit of insulin is defined as 0.04167 mg [Diem,
1962] and the most commonly used insulin is U-100 which contains 100 units of insulin
per milliliter of fluid [ADA, 1997]. Insulin injections are then adjusted based on the
results of glucose tests during the beginning stages of therapy by approximately one unit
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of insulin for each 500 mg/l over the desired glucose range [Schwartz, 1989]. The
amount of insulin needed to maintain these levels may decrease if a more continuous
means of drug delivery were adopted. It should also be noted that more dilute
concentrations of insulin (0.42 g/l (10 U/ml) vs. 20.80 g/l (500 U/ml)) are more rapidly
absorbed than higher concentrations, and deeper injections into the tissue have a faster
onset and a higher peak time. An increase in ambient temperature also aids in the
absorption of subcutaneously injected insulin [Galloway, 1990]. These aspects of insulin
absorption may affect future iterations of implantable insulin pumps.
2.4 Models of the Human Glucose-Insulin Reaction
Current treatment for diabetes mellitus is, as described above, based on an open-
loop strategy requiring that patients themselves close the loop. Patients are required to
measure their glucose levels and determine insulin dosages. The development of a
completely closed-loop approach would not only free the patient from the burden of
determining dosage levels, but it would also provide a better method for tight and
continuous control of blood glucose levels. To this end, there has been some research
into the development of a model of the human glucose-insulin reaction, which could lead
to the development of a closed-loop system.
Many initial forays into glucose-insulin modeling produced systems that were
general, not designed for individual patient simulations, and based mainly on non-
physiological mathematical functions. Lehmann and Deutsch (1992) developed a more
advanced system that incorporated basic information from some of these earlier systems
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and also included a model of glucose pharmacodynamics based on experimental data.
They claimed that their model had the ability to adapt to individual patients and that it
could predict the blood glucose profile expected from an adjustment in diet and from
insulin injections. The anatomical basis of this model is that of a patient completely
lacking endogenous insulin secretion. The model allowed different parameters to be
applied for specific patients. The goal of this model was to aid physicians in determining
an appropriate regimen for specific patients using a minimum amount of insulin, with
possible future applications in automated insulin dosage systems [Lehmann and Deutsch,
1992].
The Lehmann and Deutsch (1992) model was based on four differential equations
and twelve auxiliary relations, along with the experimental data from Guyton et al.




where I is the plasma insulin concentration, Iabs is the rate of insulin absorption, Vi is the
volume of insulin distribution, and ke is the first-order rate constant of insulin
elimination. The second equation deals with the build-up and deactivation of the active
insulin pool, Ia, and is assumed to obey first-order kinetics:
dla=kiI-k 2 la
dt
where k, and k2 are first-order rate constants describing the delay in insulin action. The
change in glucose concentration with time is given by the third differential equation:
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dG = Gin(t) + NHGB(t) - Go0 t(t) - Gren(t),
dt VG
where G is the plasma glucose level, Gi, is the systemic appearance of glucose as a result
of glucose absorption from the gut, Gut is the overall rate of peripheral and insulin-
independent glucose utilization, NHGB is the net hepatic glucose balance, Gren is the rate
of renal glucose excretion, and VG is the volume of distribution for glucose. The amount
of glucose in the gut, Ggut, following the ingestion of a meal containing carbohydrates is
defined in the final equation:
d(Ggut) = Gempt - kgabs Ggut
dt
where Gempt is the rate of gastric emptying and kgabs is the rate constant of glucose
absorption from the gut into the systemic circulation. The auxiliary equations are used to
describe such model elements as the rate of insulin absorption, the steady-state insulin
profile, and the duration of the period during which gastric emptying is constant and
maximal [Lehmann and Deutsch, 1992].
The results of Lehmann and Deutsch's (1992) model show fairly accurate results,
but there are some inherent problems with the model. The model itself was kept
intentionally simple, making certain broad assumptions such as that insulin absorption
and elimination depends solely on body weight. Other issues such as the role of ketones
and the change in renal threshold of glucose for elderly patients were not included in the
model. The authors state that this model cannot be applied to all patients under all
conditions [Lehmann and Deutsch, 1992], and as such, it would need further modification
before it could be used reliably in a commercial product.
21
Another model was developed by Parker, Doyle, and Peppas (1999) which built
on Lehmann and Deutsch's model. This model combines empirical approaches which
capture system behavior from input-data output (such as insulin injections and related
glucose excursions), together with additional physiological details such as insulin
dynamic behavior and kinetics. This model is based on a linear step-response which
estimates future output based on a series of past inputs. A linear approximation of the
output can therefore be calculated when a past input profile is given:
y'(k) = s(i) A u(k-i) + s(M) u(k-M-1)
where y'(k) is the predicted output, s(i) is the step-response coefficient, u is the past
input, and M is the number of sample times. In this equation, the first term represents the
response of the model to the input change, and the second term represents the steady state
of the process prior to the input change. The step-response coefficients can be calculated
from an identified impulse-response model of the system:
y(k)= h(i) u(k-i) and
s(k) = h(i)
where h(i) are the impulse response coefficients [Parker et al., 1999].
The Parker et al. (1999) model shows a strong correlation between predicted
glucose levels and those achieved using a nonlinear diabetic patient model, however no
data are shown to compare these predicted levels with actual patient measurements. The
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authors are also working on adding parameters to the model related to food intake and
exercise as well as other factors that may affect glucose levels [Parker et al., 1999].
Although this model shows much potential, it has yet to be proven that a purely
mathematical approach can be applied to the physical realities of diabetes mellitus
treatment.
Many other models of the human glucose-insulin response have been proposed
such as linear, non-linear, probabilistic, compartmental, non-compartmental, and
parametric models [Bremer and Gough, 1999]. Many of these approaches have proved
useful in research environments, however their scope has been very limited in clinical
applications. Most of these methods rely on continuous or frequently updated data, and
continuous sensors which are able to provide these data are still only in the research
realm. However, it has been shown that even a simple linear model can accurately
predict glycemic excursions in humans for up to ten minutes with very high accuracy
[Bremer and Gough, 1999]. Future models will also have to take into account the fact
that normal insulin secretion is signaled by neural and hormonal messengers before
glucose levels actually begin to rise. In this way, insulin is immediately available when
blood glucose levels begin to increase rather than allowing the glucose levels to rise
dramatically before there is enough insulin to start the regulation process. This type of
neural and hormonal sensitivity needs to be pre-programmed into automatic closed-loop
controllers to ensure proper glucose regulation [Reboldi et al., 1991]. By further studying
this phenomenon, gathering more patient data, and increasing efforts into the
23
development and commercialization of continuous glucose sensors, it is possible that a
closed-loop system may someday provide better glucose control to diabetic patients.
24
Chapter Three: Current Technology for Glucose Sensing and Insulin
Delivery
3.1 Devices Currently Available for Glucose Testing
The goal of current approaches to the control of diabetes mellitus is to keep blood
glucose levels as close to normal as possible. Currently, the best way to achieve this is
through frequent monitoring via self-administered glucose tests coupled with insulin
injections and dietary adjustments. Many types of glucose tests currently exist, but few of
these have been shown to be truly reliable under all circumstances. Some of the tests,
including those derived from samples of urine, sweat, and saliva, reveal average values for
glucose levels during the past few hours, but do not indicate what the present levels are.
These tests are also patient dependent, as the relation between the level of glucose in the
blood and in these other fluids varies for each person.
By testing their blood, patients can get an accurate reading of the current glucose
levels in their bodies. This type of testing is done by pricking the finger with some type of
lancet to obtain a drop of blood, which is then placed on a special test strip. In one
technique for testing, the test strip has been chemically treated and will change color
according to detected glucose levels. The strip is then compared to a color chart to
determine the current glucose range. In another more common technique, the test strip
with the impregnated blood is placed in a meter which detects the glucose levels using
electrochemical sensors. This method gives a more precise value of the glucose level.
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Some of these meters are able to store previous test results for future analysis [Ginsberg,
1992; Tamborlane and Amiel, 1987].
Glucose meters, lancets, and test strips come in many different shapes and sizes.
Scanning through any magazine for diabetics, such as ADA's "Diabetes Forecast," shows
that many different companies are marketing these types of devices. However, this
technique has many drawbacks. Although it has been shown to be the most accurate
method for glucose detection available, it is far from flawless. An evaluation of six
popular blood glucose meters in 1996 showed that there were substantial differences
between the readings recorded by different meters during hypoglycemia. Using 119
different glucose concentrations, 663 different readings were recorded. The correlation
coefficients between the meter readings and the glucose reference values of the tested
meters ranged from 0.78 to 0.93, and as many as 7% of the readings fell outside 40% of
the reference values [Trajanoski et al., 1996]. Another evaluation of six blood glucose
meters in 1998 also found that the performance of home blood glucose meters varied
significantly within expected glycemic ranges [Brunner et al., 1998].
In addition to issues of meter accuracy, there are other factors that affect the
reliability of patient use of glucose meters. Many sources of error in patient glucose meter
readings relate to how the patient uses the meter and include the use of inadequate
quantities of blood, faulty timing, and improper calibration of the meter [Tamborlane and
Amiel, 1987]. Another issue for diabetics is the fact that insurance companies do not
usually cover the cost of the glucose meters or the test strips which must be thrown out
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after a single use. Finally, one of the most significant issues is the fact that this technique
involves drawing blood. As doctors are recommending a minimum of four glucose test
each day, this means at least four painful finger pricks each day with little time for old
wounds to heal as well as an increased risk of exposure of the general population to
infection and blood transferred diseases such as HIV and hepatitis.
The pain associated with lancing and often a phobia of the needles themselves
discourage many diabetics from testing often enough or even from testing all together.
Without these vital glucose tests, patients run an extremely high risk for many diabetic
complications. There are a few new devices such as that offered by Chronimed [D'Arrigo,
1999], that try to eliminate the use of actual needles by using a laser lancing device to
puncture a hole in the skin. Chronimed's device uses an Erbium YAG 2940 nm laser and
penetrates the finger 0.6 - 2.4 mm. The entire device size is 250 mm x 100 mm x 50 mm.
While this device is still somewhat painful, the discomfort is supposed to subside faster
than the pain associated with traditional lancing. This device does take some training to
use and is prohibitively expensive at $1000 - $2000 for the unit and costs about 15 cents
for the single-use disposable shield used for each test. However, for those with extreme
needle phobias, it does offers a needle-free approach to glucose testing [D'Arrigo, 1999].
Much research is currently being done to try to develop a painless glucose sensor
for diabetic patients. The most recent developments have come from MiniMed [MiniMed,
1999] with FDA approval of their continuous subcutaneous glucose monitoring system,
which MiniMed eventually hopes to combine with an insulin pump. The sensor in this
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system is designed to be inserted into subcutaneous tissue and worn for three days using a
system of insertion directly beneath the skin, similar to that used in MiniMed's insulin
pumps [MiniMed, 1999]. A similar type of insertion system was patented in 1994 by Eli
Lilly and Company [Mastrototaro, 1994]. The sensor is attached with a wire to a pager-
sized glucose monitor which records the sensor readings during the three day period. The
monitor measures approximately 9 mm x 7 mm x 2 mm and weighs 100 gm. The sensor
records electrical signals proportional to glucose levels in the subcutaneous tissue and
takes readings every ten seconds, storing only 5 minute averaged values. While this is a
major step in the direction of continuous sensing, it is still not designed for regular patient
use. The current sensor simply stores values until the physician downloads the
information to a personal computer for analysis. It does not give feedback to the patient
during use, and the stored information is only available after 72 hours. According to the
FDA approval, these systems are only to be used as a supplement to, and not a
replacement for, standard glucose testing. The information generated is intended as a
guide for future management and not as a means to adjust immediate insulin dosages
[MiniMed, 1999]. The sensor also still requires several finger-prick tests a day for
calibration purposes and to check sensor accuracy [Jacobs, 1999].
Another device is the GlucoWatch being developed by Cygnus. This device is still
pending FDA approval, but Cygnus hopes to obtain approval within the first quarter of
2000. The GlucoWatch operates by sending a low amplitude electrical current into the
skin to open the pores and then extracts interstitial fluid which resides below the outer
layer of the skin and contains information on body glucose levels. The extracted fluid
28
contacts an electrochemical sensor which can detect current glucose levels, and the
reading is presented digitally on a watch display. The GlucoWatch aims to be a painless
device that can take frequent readings and so lead to better diabetes control. Clinical
research on the GlucoWatch has shown that variations in physiological factors and
environmental factors, such as temperature, as well as common drugs do not affect the
accuracy of the device. Pricing estimates have placed the watch itself at $175-$200 and
the consumable sensor at $2.75 a piece. The sensor needs to be replaced every twelve
hours [Cygnus, 1998].
Although there is current work being done towards the development of a painless
glucose sensor, patients are still forced to rely on more traditional methods for verification
of the newer devices' readings according to both FDA requirements and manufacturers'
specifications. These methods involve painful finger pricks that are aversive for many
diabetics. In addition, none of these methods combine glucose sensing with insulin
delivery. As such, there is a large opportunity in the field for the development of an
accurate system that can replace these traditional methods.
3.2 Devices Currently Available for Insulin Delivery
The two primary methods for insulin delivery currently available to diabetics are
manual injections of insulin and insulin pumps.
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3.2.1 Insulin Manual Injection
The most traditional method of insulin delivery is through insulin injections.
Patients are advised by their physicians as to the amount and type of insulin that should be
administered and at what times during the day. Dosages are adjusted according to
individual lifestyles. Conventional approaches tend to advocate only one or two injections
a day, whereas tighter control calls for up to four injections a day to try to mimic more
closely normal human insulin production [DCCT, 1993]. This method of delivery entails
the use of syringes. Patients must be trained how to use the syringe as well as how to
dispose of the needle.
Some companies are working to eliminate the use of syringes for insulin delivery
which are often perceived as daunting by prospective users. One option currently on the
market is the jet injector marketed by Medi-Ject. This type of injector uses a high-speed
stream of insulin itself to penetrate the skin. The stream has a diameter of about 150 pin,
which is about half the diameter of a standard needle. While not all patients find this
method effective and it can be painful, it does eliminate the need for actual syringes. The
cost of these devices can be in the order of $400, and some insurance plans do cover jet
injectors. While this is not a perfect solution, many patients prefer these devices to
conventional syringes [Medi-Ject, 1999].
Another alternative to the bolus injection method may be through pulmonary drug
delivery. Phase III clinical trials are currently being conducted by Pfizer, Inc. on the
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delivery of insulin through an inhaler-type device. Previous studies have shown that
inhaled insulin achieves the same blood glucose control as that obtained with traditional
injections in both Type 1 and Type 2 diabetics [Patton, 1998; Walsh, 1998]. While this is
not yet a commercially available option, there is definitely promise in this type of delivery
system.
3.2.2 Insulin Pumps
The second major category of insulin delivery is the insulin pump. An insulin
pump is a pager-size device containing a reservoir of insulin. Connected to this reservoir
is a catheter with a needle at the end which is inserted into subcutaneous tissues, usually in
the abdomen. The catheter needs to be replaced every 2-3 days. The pump is then
programmed to deliver a basal, or continuous, infusion of insulin usually in the range of
0.35 to 1.38 ptg/s (0.5 to 2.0 units/h). Premeal boluses are then administered
automatically according to the therapy regimen about thirty minutes before mealtime.
Approximately 40-50% of the patient's total daily insulin dose is delivered by the basal
rate infusions during a 24 hour period. The remaining insulin is then divided between the
bolus injections. The program can be adjusted for varying activities and meals,
accommodating to the lifestyles of individual patients. The insulin used is regular insulin,
making insulin absorption by the body more predictable [Strowig and Raskin, 1990].
Many current pumps are being designed with communications capabilities with the hope of
interfacing these pumps with glucose sensors for better feedback control in the future.
Approximately 6 to 8% of Type 1 diabetics currently use insulin pumps. However, 60%
of the medical community who are also diabetic (including physicians, endocrinologists,
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nurses, and diabetes educators) use insulin pumps to control their insulin levels due to the
more regular rates of insulin infusion [Noonan, 1999].
While insulin pumps have many advantages, such as the potential for a more
flexible lifestyle, and offer a more normal schedule of insulin infusion to the body, there
are some risks associated with their use. Interruption of insulin delivery can lead to a
rapid deterioration of diabetic control. Since the insulin used is short acting and there is
no build up of insulin in the body, an interruption of regular pump operation can lead to
hyperglycemia in a matter of hours. As insulin pumps also operate while patients are
sleeping, a problem may not be readily detected, and patients could deteriorate
considerably while they are asleep. Patients must be made aware of these types of issues
before beginning treatment with a pump [Strowig and Raskin, 1990]. Another
disadvantage is that the pump must be worn at all times, including during bathing,
swimming, sleeping, and intimacy, although short periods of pump disconnection can be
tolerated [Koivisto, 1988].
3.3 Glucose Sensor Design Methods in Research
The original approach to improving the control of diabetes mellitus was to create
an entire artificial pancreas consisting of a glucose sensor and insulin pump. In 1974 one
such device was tested on human subjects. This system was shown to provide very good
control of blood sugar for diabetic patients using less than half of the daily insulin
requirements of the traditional insulin delivery mechanisms [Albisser et al., 1974].
However, further work in this area was hampered by the technology of the time. The
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need for large computers, sensors, and pumps meant that this was not an implantable
system and that it could not be used outside of a clinical environment. Work continued
into the 1980s [Shichiri et al., 1984], but none of these devices ever achieved real clinical
success due to the issues listed above. Current technological advances now allow for the
miniaturization of such systems and there is hope that a true artificial pancreas will soon be
a reality. To this end, much work is being done to develop miniature glucose sensors
using a variety of different methods.
3.3.1 Optical Techniques
One method of glucose detection, which has been investigated since the 1970s, is
to shine a light into the patient's eye, measure the reflected radiation, and compute the
spectral absorption of the aqueous humor which is claimed to be proportional to the blood
glucose level. Patents have been issued for this type of process from 1975 through 1998,
however, none of these devices has been shown to be accurate for large numbers of
patients. While the method is noninvasive, the device itself is not easily used without
assistance as it entails shining lights at specified positions into the eye [Hattori and
Ushizawa, 1998; March, 1976, 1977; Miyagawa and Toida, 1998; Stark, 1995].
A related method radiates the patient's skin with a light source, such as infrared
illumination, and measures the glucose levels via light absorption, polarization of the light,
or characteristic wavelength shifts using Raman spectroscopy. Again, many patents for
these types of procedures have been issued, but no such devices have yet been approved
for clinical use in the United States for several reasons [Ariizumi and Higashio, 1996;
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Buchert, 1995; Clarke and Wang, 1993; Elmerick and Peters, 1999; Kim and Yang, 1993;
Steffes and Tarr, 1993]. Many of these methods suffer from low sensitivity, low accuracy,
poor selectivity of glucose signals, and dependence on personal characteristics of the
patient at the measurement site [Wilkins and Atanasov, 1996]. These devices also tend to
be large and expensive. Work continues on these methodologies with the hope that such a
completely noninvasive method for sensing can one day be used.
3.3.2 Chemical Techniques
The most common method of glucose sensing uses an electrochemical sensor with
the immobilized catalyst glucose oxidase (GOx) used to spur the reaction that detects
glucose (see Chapter Four for a discussion of this reaction). This type of sensor has been
shown to be accurate and reliable for the majority of patients, and is currently used in both
standard glucose meters and in implantable sensors. There are numerous patents for
glucose sensors using this type of method, and they are available in a variety of shapes
(disks, needles, etc.) and sizes (macro-scale to miniature sensors). GOx sensors have been
fabricated that can sense glucose both internal and external to the human body. Sensing
blood glucose levels in this way has also been approved by the FDA in a variety of
applications. Some of the major difficulties with these types of sensors have been size,
stability, and interference with the measurement from other bodily substances. Research is
currently being done to investigate better methods of electrochemical sensor fabrication
and enzyme immobilization. Table 3.1 lists a few of these methods indicating areas of
major differences. Many other methods exist, but most seem to employ similar techniques
to those listed.
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Authors Working Immobilization Working Response Maximum Sensor
Electrode material for Potential Time current Stability
GOx vs. (seconds) achieved (months)
Ag/AgCl (10- 5A/M
(volts) glucose)
Yao, 1983 Platinum BSA and +0.7 10 1
glutaraldehyde (vs.SCE)
Gunasingham, Platinum BSA 60
et al. 1989
Moussey, Platinum BSA and +0.7 20-40 2 0.5
et al. 1993 glutaraldehyde
Steinkuhl, Platinum Gelatin +0.6 65-104 1.5
et al. 1996
Li, et al. Platinum Pyrrole +0.2 30 60 6
1998 (vs.SCE)
Lukachova, Platinum DMF 35
et al. 1998
Bindra, et al. Platinum CA and +0.6 0.4 1
1991 -Iridium glutaraldehyde
Wang, et al. Rhodium Rhodium +0.3 9
1992
Yang, et al. Rhodium BSA and +0.25 10 5 3
1998 glutaraldehyde
Furbee, et al. Carbon Pyrrole +0.7 14 0.2 2
1998
Milardovic, Nickel BSA and -0.2 0.05
et al. 1997 glutaraldehyde , I _II
Table 3.1 Various methods of electrochemical glucose sensor fabrication
BSA = Bovine Serum Albumin, SCE = Standard Calomel Electrode,
DMF = Dimethylferrocene, CA = Cellulose Acetate
Possible interference from other bodily substances is a major concern in the
fabrication of electrochemical sensors. The main interferents for the glucose sensor are
uric acid, acetaminophen, and ascorbic acid. In order to avoid these types of interferents,
additional coatings are added to the sensor surface which act as semipermeable
membranes. One popular coating of this kind is Nafion (developed by DuPont). An
undesired side effect of Nafion is that it reduces the amperometric response of the sensor
dramatically, necessitating the use of a more sensitive meter for recording currents [Yang
et al., 1998]. One must also be sure that if the sensor is implantable, the coatings used are
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biocompatible. Other types of coatings such as polyvinyl chloride (PVC) are also under
investigation [Christie et al., 1992].
3.4 Problems in Painless Monitor Development
One of the major problems encountered by physicians in treating diabetics is that of
convincing the patients to monitor their glucose levels closely. The pain and
inconvenience of monitoring are often sufficient discouragements to dissuade people from
performing these tests regularly. New research is trying to address this problem by
creating painless (or at least less painful) ways to test glucose. However, these methods
are still required to meet the standards that are currently achieved by traditional testing
methods. These include a fast response, accurate readings, and stability so sensor readings
can be appropriately analyzed [Gough and Armour, 1995].
In the search for an implantable alternative to the glucose sensor, many researchers
have tried to develop short-term subcutaneous implantable sensors [Johnson et al., 1992;
Pickup et al., 1993; Poitout et al., 1993; Shichiri et al., 1982; Shichiri et al., 1986]. These
sensors present serious difficulties due to problems such as signal stability and sensor
lifetime. They are typically implanted for a period of several days, and results have shown
that they produce a reliable response to blood glucose under ideal conditions. Although
these results have looked promising, there are still a number of issues which need to be
addressed, in particular the decay in sensitivity over time. In many of the published
experiments, the reported results are based on signals that were recalibrated after the
experiment [Gough and Armour, 1995]. This technique does not allow for analysis of the
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decay in the actual signal. To overcome this, a more sophisticated method of calibration
must be determined. The other problem with these implantable sensors is that improper
insertion may lead to tissue inflammation and blood pooling which can interfere with the
sensor signal [Gough and Armour, 1995]. Studies need be conducted which look at the
effects of sensor insertion and the reliability of signals from the sensors. To understand
fully how these sensors act in vivo, a valid model of glucose transport in living tissue must
be determined. This is an area that is severely lacking in glucose sensor research
conducted to date [Gough and Armour, 1995].
3.4.1 Continuous Monitoring
There are two main approaches to developing a continuous glucose sensor. One is a
percutaneous sensor such as a needle placed in the skin with a wire outside the body
connected to a readout device. The second approach is an entirely implantable device that
would communicate to an external receiver using radio telemetry. Both of these methods
need to deal with the body's response to a foreign substance. The body's natural response
is to encapsulate the foreign element in order to protect the rest of the body. The hope is
that percutaneous sensors will be able to obtain signals before this response takes place. A
fully implanted sensor would need to have some way of dealing with this issue on a long
term basis. A minimally invasive means of implanting the sensor would need to be
developed. The fully implanted sensors also need to be larger than the percutaneous ones
in order to survive in the body for long periods without requiring replacement (current
designs require a battery of approximately 5 mm height and 20 mm diameter). The
advantage of such a sensor would be that patients would not need to monitor their glucose
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levels on a daily basis. Percutaneous sensors, on the other hand, do not involve any
surgery and can be placed on the body by the patients themselves. There may, however,
be a risk of infection at the insertion site of such sensors [Henry, 1998].
There are many hurdles that exist in the search for an effective sensor. As previously
mentioned, biocompatibility remains a very important issue. Other issues are the need for
recalibrating the sensor, the lack of understanding of the relationship between blood
glucose levels and those found in other tissues, interferents from other bodily substances,
and safety and stability issues. All of the existing sensors require daily recalibration with
traditional fmgerstick sensors [Henry, 1998].
3.5 Glucose Levels through Interstitial Fluid Sampling
One of the more recent approaches to painless glucose monitoring is to determine
what other substances in the body can give accurate glucose measurements. One such
substance that has been closely investigated is the interstitial fluid (IF) which resides in the
outer layer of skin. The skin itself is the largest organ of the human body (approximately
2 square meters) [Sherrick and Cholewiak, 1986], and thus access to IF can be obtained at














Figure 3.1: Diagram of human skin [Adapted from Repechage, 1999].
The epidermis is the outer layer of the skin and is approximately 100 im thick. The
epidermis itself is comprised of various layers. The outermost layer is the stratum
corneum, made by the layering of thin cells, and is typically about 10 ptm thick [Sherrick
and Cholewiak, 1986]. Below this are layers of epithelial cells [Repechage, 1999], and the
IF flows between these cells. Since the epithelial cells are found above the nerve endings
and capillaries, accessing the IF to measure glucose could be a painless and bloodless
process if done correctly.
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Since IF is a bodily fluid that could be accessed without pain, it is necessary to
determine whether it contains information such as glucose levels in the body which would
lead to more options for glucose sensing. Many such studies have been carried out and
have shown that there is a positive correlation between IF glucose levels and blood
glucose levels [Bantle and Thomas, 1997; Rebrin et al., 1999; Tamada et al., 1995].
Experiments have also shown that the IF glucose profile is slightly shifted in time as
compared to the blood glucose levels, indicating that a lag exists between these two fluids.
In one study where IF was extracted from the body, a process which took 20 minutes per
extraction, the lag time was no more than one test interval [Tamada et al., 1995]. Other
groups have shown the delay to be between 3 - 14 minutes. This delay can be
compensated for by the use of a simple digital filter [Rebrin et al., 1999].
The Tamada et al. (1995) study also showed that 95% of glucose measurements
taken using IF match conventional blood glucose measurements. This level of accuracy is
similar to that obtained with commercially available blood glucose monitors, which shows
that IF measurements are reproducible and reliable [Tamada et al., 1995]. Other studies
have shown a high correlation between IF, capillary, and plasma glucose levels in diabetic
subjects. A correlation coefficient of 0.95 was obtained when plasma glucose was
compared with IF glucose, and a correlation coefficient of 0.87 was obtained when plasma
glucose was compared with capillary glucose in a group of 17 diabetic subjects. Capillary
blood glucose levels, therefore, were shown to have no higher correlation with plasma
glucose levels than the values obtained using IF [Bantle and Thomas, 1997]. Although it
has been argued that IF glucose concentrations are significantly different from plasma
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values and that IF levels may lead or lag the plasma values by as much as 45 minutes,
many of these latter studies have technical variations in methodology including different
implantation sites, device operation, and sensitivity. All of these factors have influenced
the results achieved. When more careful and consistent measurements were done, it
appears that IF does in fact reflect accurately the glucose levels in both capillaries and
plasma [Rebrin et al., 1999].
Many different methods of testing IF have been proposed. The majority of these
require the extraction of a small amount of IF for external testing. One popular method is
to form a small erosion on the outer layer of skin using a mild suctioning technique to
expose the IF for collection. The advantage of this approach is that after testing, the outer
layers of the epidermis regenerate rapidly. Svedman and Svedman (1998) used this
method to study both diabetic and non-diabetic subjects, in which a skin erosion was
formed in 15-70 minutes. Another suction cup was then placed over the erosion in order
to extract the IF. This process took another 20 minutes and extracted 5 p1 of IF. The
glucose level in this small volume of IF was measured, and results were compared with
capillary and plasma glucose levels to verify their accuracy. It was found that this method
caused minimal discomfort consisting of a light tingling sensation during the formation of
the erosion. As the same site was used for IF extraction over a 6 day period, it was found
that on the final day less than 5 p1 could be extracted from some subjects. There was a
slight pigmentation of the skin after testing which the subjects considered trivial [Svedman
and Svedman, 1998]. Other studies using this technique showed similar extraction rates
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and confirmed a 10 to 20 minute delay in IF glucose levels as compared to blood glucose
levels [Kayashima et al., 1992; Kimura, 1993].
Another method of accessing IF is by applying a small current across the skin,
creating a perm-selective membrane which allows certain ions to flow through the skin.
The current used in this method is 2.5 A/m applied for 60 minutes. It was found that
periods of less than 15 minutes yielded contaminated samples which skewed test results.
The results indicated the average blood glucose level during the sampling interval and not
the current blood glucose level. Patients experienced mild tingling sensations from the
application of current to the skin surface, but this generally lasted no longer than 30
minutes [Rao et al., 1995].
Although these methods are promising, they are still not ideal. They do not allow
for long-term continuous monitoring of glucose and IF collection and testing time is long
(15-20 minutes). Many companies are working to find more viable methods for a
commercial product. The current leaders in this field are MiniMed, Cygnus, Integ, TCPI,
and SpectRx. SpectRx uses a laser to create micropores in the skin to provide access to
IF. Integ's technology creates small holes in the dermis through which IF samples are
collected. Current MiniMed and Cygnus technologies were discussed in Section 3.1.
TCPI uses a transdermal patch which is able to draw out the IF [Mendosa, 1997]. While
many of these products look promising, none has yet received FDA approval. In addition,
high production costs have hampered the development of these new devices.
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Chapter Four: Theory of Sensor Fabrication and Measurement
4.1 Enzyme Kinetics
One of the most successful types of sensors developed for glucose detection uses
an enzyme to catalyze an electrochemical reaction (see Section 4.2). It is therefore
necessary to understand the chemical kinetics of such a reaction.
A catalyst is defined as a substance that speeds up the rate of a reaction and is
regenerated to its original state after the reactant has been converted to products. All
catalyzed reactions lower the required activation energy of the reaction. Enzyme
catalysts are also able to catalyze certain reactions selectively and discriminate against
others. The enzyme itself is a protein with one or more active sites where the reaction
takes place. The active site is thought to have a rigid structure while the substrate
molecule has a complementary structure, a feature that may account for the selective
abilities of the enzyme [Chang, 1981].
An important aspect of enzyme kinetics is the initial rate (v") of a reaction. This
quantity is important for several reasons:
1) The rate of the reverse reaction needs to be minimized. This rate increases
with the product concentration.
2) During the reaction, there may be significant heat or pH changes that may
change the reaction rate.
3) The product may bind to the enzyme and inhibit its ability to function.
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4) The initial rate corresponds to a known fixed concentration of substrate which
will decrease with time.
It can be shown that at low concentrations of the substrate [S], the reaction rate increases
rapidly and then gradually levels off at higher concentrations. The relationship between
rate and concentration can be defined as:
vo = a [S ,
b + [S]
where a and b are constants [Chang, 1981].
Enzyme reactions using a single substrate can be expressed as:
ki k2
E+S ES * P+E,
where the substrate S combines with the enzyme E, forming an enzyme-substrate
complex. This complex subsequently breaks down into the products P and the freed
enzyme. ki, k -1, and k2 are kinetic constants of the particular reactions [1/s]. A short
time after the enzyme and substrate are mixed, the concentration of the enzyme-substrate
complex reaches a steady-state value. Using this steady-state approximation and the rate
equation above, the Michaelis-Menten equation can be derived:
v. = _Vm S]
Km + [S]
where Vm is the maximum rate of the reaction and Km is the Michaelis-Menten constant.




When the initial rate is half of the maximum rate, the value of Km is equal to the substrate
concentration [Chang, 1981].
It is also important to note that the activity of many enzymes varies with pH.
These enzymes have a characteristic pH at which they have a maximum activity level.
Varying the pH in either direction from this optimal point will decrease the enzyme
activity. Enzymes that are active within cells generally have an optimal pH close to the
range of the cells' normal functioning pH [Chang, 1981].
4.2 Amperometric Sensor for Glucose Detection
The most common type of sensor used for glucose detection is an electrochemical
sensor that uses the enzyme glucose oxidase (GOx) to catalyze a reaction with glucose.
Glucose can be detected amperometrically by a two-step chemical process. GOx
catalyses the oxidation of P-D-glucose, in which the glucose breaks down into hydrogen
peroxide and gluconic acid. Electrons are then extracted from the hydrogen peroxide
through a subsequent oxidation step (Figure 4.1) [Wilkins, 1996].
GLUCOSE +0 GLUCOSE OXIDASE GLUCONIC ACID +1H202
H202 OXIDIZED by ELECTRODE 2H++ 2 +2e
Figure 4.1: Chemical reactions involved in glucose detection.
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A circuit can now be set up to measure the resulting current produced from this reaction.
The current measured in this circuit will be linearly proportional to the amount of glucose
present in a fluid such as the IF (Figure 4.2).
IF GOx
Working Ag/AgCl reference
Electrode---* , --- electrode
-- H202
Figure 4.2: Circuit to detect amount of glucose in IF.
Ag/AgCl = Silver/Silver Chloride.
This is the type of method used by the researchers cited in Chapter 3. With different
reference electrodes, different activating potentials are required, as shown in Table 3.1.
4.3 Using Microelectrodes for Chemical Sensing
The use of microelectrodes for chemical sensing has opened up a new realm of
possibilities in sensor development. The term "microelectrode" is generally used for
electrodes having at least one dimension not greater than 25 im. With the ability to
miniaturize electrodes, the potential now exists to explore certain microscopic domains,
measure local concentration profiles, detect microflow, and analyze very small sample
volumes. Studies have expanded to single cell recordings in the brain and high resolution
characterization of surfaces [Wang, 1994].
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Microelectrodes have many characteristics that are lacking in standard electrodes.
Among these are a relative immunity from certain resistance effects, high rates of mass
transfer which yield higher sensitivity, and high signal-to-noise ratios [Glass et al., 1990].
The improvement in signal-to-noise ratios for microelectrodes is due to the fact that the
electrical signal is proportional to the total geometric area, whereas the noise is
proportional to the active element area only [Penner and Martin, 1987]. Microelectrodes
can also be used for measurements in unconventional environments without needing
additional supportive electrolytes. Many of these advantages become even more apparent
when microelectrodes are used in arrays [Glass et al., 1990].
Currents at these types of electrodes are very small, and therefore the
microelectrodes are essentially nondestructive to the item under observation. The small
current also allows microelectrodes to be used in solutions with very high resistance
which were previously inaccessible to conventional electrodes [Wightman, 1981]. The
double-layer capacitance of microelectrodes is significantly smaller than that of
conventional electrodes, and so they form electrochemical cells with small RC time
constants. This feature allows for very high speed voltammetric experiments, at scan
rates higher than 106 V/s. This permits the study of kinetics of high speed electron
transfer and associated chemical reactions. In addition, the mass transport rate to and
from an electrode increases as electrode size decreases. Not only does this enhance the
signal-to-noise ratio, but it also means that steady-state currents are obtained with very
short settling times [Wang, 1994].
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Microelectrodes can be fabricated in a variety of shapes. The common feature of
all styles is that the electrode diameter is significantly smaller than the diffusion layer at
the electrode surface. Cylindrically shaped microelectrodes can be several millimeters
long and yield a large current while maintaining the other benefits of a microelectrode
[Wang, 1994].
Since the benefits of microelectrodes become amplified when they are used in an
array format, which includes a proportional increase in the current detected due to the
increased number of electrodes, a large potential exists for the use of such electrode
arrays in conjunction with drug delivery techniques. Specifically, since the IF lies on
average about 50 pm from the skin surface, use of this type of micro-array to access the
IF could lead to the development of a potentially painless glucose sensor and insulin
delivery system. Only a few groups have tried micro-array formats for drug delivery. A
group at the Georgia Institute of Technology has started to publicize success with drug
delivery using micro-needle arrays [Henry et al., 1999]. The goal of their work was to
puncture the stratum corneum with a micro-needle array to increase the permeability of
the skin. The array was then removed and the required drug (calcein) was applied to the
punctured skin surface. The array was fabricated in silicon using a reactive ion etching
technique. The micro-needles formed in this manner were 180 tm in height and 80 pm
in diameter. It was found that these needles could pierce the skin with a pushing force
estimated at 10 N. When these needles were inserted and left imbedded in the skin,
permeability was seen to increase by a factor of 1000 over non-penetrated skin. When
the array was removed after 10s, permeability increased by a factor of 10,000, and when
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the array was removed after 60 minutes, permeability increased by a factor of 25,000.
None of the subjects experienced any pain associated with the needle insertion [Henry et
al., 1999]. This work shows that micro-needle arrays can be used successfully to access
IF and also that use of these arrays could provide a viable means for transdermal drug
delivery.
4.4 Cyclic Voltammetry as an Analysis Tool
Cyclic voltammetry is one of the most popular tools for qualitatively analyzing
electrochemical reactions. It is able to provide information on the thermodynamics of the
redox process, the kinetics of the electron-transfer reactions, and on other coupled
chemical reactions and adsorption processes. It can also locate the reaction's redox
potential quickly. Cyclic voltammetry is done by scanning the potential of a stationary
working electrode with a specified potential waveform. Most commonly, this waveform
is triangular, although cyclic voltammetry can be performed with other wave shapes,
including sinusoids. A potentiostat is then used to measure the current during the
potential sweep. The resultant plot of current versus potential for the entire cycle (or for
multiple cycles) is called a cyclic voltammogram. Peaks occur in the voltammogram
when the redox potential is reached. These peaks are caused by the formation of a
diffusion surface near the electrode surface. The peaks are characteristic of the particular
reaction taking place, and they may also shift or change shape in solutions of varying
concentrations [Wang, 1994]. Cyclic voltammetry was done with a H2 0 2 sensor to
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Figure 4.3: Cyclic voltammogram of a hydrogen peroxide sensitive electrode as the
concentration of H20 2 is increased.
Several parameters characterize the voltammogram. At 25 0C, the peak current for
a reversible reaction is provided by the Randles-Sevcik equation:
ip = (2.96 x 10') n32 A C Do "2v 2
where n is the number of electrons transferred, A is the electrode area (m2), C is the
concentration (M), D is the diffusion coefficient (cm2/s), and v is the scan rate (V/s).
Another characterizing feature is the separation between peak potentials which can be
used to determine the number of electrons that have been transferred. This separation is
given by:
AE = 0.059 V.
n
A fast one-electron process will have a AE of about 59 mV. These peak potentials are
independent of the scan rate used for the experiment. In reversible processes that consist
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of multielectron transfers, the cyclic voltammograms show several distinct peaks that
depend on the separation of the potentials for the individual steps. For an irreversible
process, the individual peaks will have smaller amplitudes and be widely spaced. A
completely irreversible system will display shifts in the peak potentials as the scan rate
changes [Wang 1994].
Cyclic voltammetry is very useful for the qualitative diagnosis of chemical
reactions. Changes in the shapes of the voltammogram can be used to identify the
reaction pathways and indicate the presence of reactive intermediates. Information on the
rates of reactions can also be obtained by adjusting the scan rate used. Common scan
rates are usually between 0.02 and 200 V/s [Wang, 1994]. Faster scan rates of up to 106
V/s can be used when microelectrodes are used instead of more conventionally sized
electrodes. This ultrafast cyclic voltammetry has three major applications. The first of
these is the ability to detect short-lived species generated by the reaction (with life times
as short as 25 ns). Subsequent chemical reactions due to these species can then be
investigated. Therefore, by using high speed cyclic voltammetry a picture of the transient
species produced by a chemical reaction is obtained, which is information that would be
lost with the slower scan rates of conventional electrodes. The second application is the
measurement of rate constants for fast interfacial electron transfer. This is achieved by
using fast scan rates that do not allow the diffusion layer to form completely, and so
currents that reflect planar diffusion at the electrode surface can be obtained. The third
application is the determination of the formal potential for reactive products of electron
transfer [Penner et al., 1991].
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Cyclic voltammetry can be coupled with microelectrodes to characterize in-vivo
chemical reactions such as the detection of glucose. The resulting voltammograms can
be compared to determine the presence of various reactants in order to deduce the actual
reaction that is taking place. In in-vivo applications, these differences in voltammograms
can be used to help identify possible signal interferents that may affect measurements of
levels of fluid such as glucose.
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Chapter Five: Sensor Fabrication Experimental Results
5.1 Sensor Fabrication Experiments
Since amperometric glucose sensing has been shown to be the most accurate
method available to detect glucose, it was used for the sensors of this research. Initially,
glucose sensor fabrication followed an electrochemical deposition method described by
Yang et al. (1998) (see Table 3.1). In this method, the outer surface of a needle is made
into an amperometric glucose sensor by coating it with various layers. The coatings are
formed using a series of potentiostatic (constant potential) and galvanostatic (constant
current) chemical depositions. This particular method was chosen because the resulting
sensor was stated to have a quick response time to glucose (10 seconds), a low operating
potential (+0.25 V), sensor stability lasting three months, immunity to chemical
interferents, a straightforward fabrication method, and the potential for miniaturization
[Yang et al., 1998]. Using this method, 1.02 mm diameter (18-gauge) stainless steel
needles were consistently sensitized to hydrogen peroxide, the intermediary reaction
product, as seen in the data collected from one multi-layered needle (Figure 5.1). The
results show a distinct and constant rise in current as the hydrogen peroxide concentration
increases which follows a second-order model:
i = -0.54 C2 + 22.18 C + 6.92
where i is current in ptA and C is concentration in mM. This increase in current was
evident throughout the expected biological range of hydrogen peroxide concentrations (0
- 20 mM) and the rise time of the response was less than 5 s. It is expected that this
response will reach a saturation point as the concentration greatly exceeds 20 mM due to
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Figure 5.1: Sensor response to hydrogen peroxide.
The H202 sensor was coated with GOx in a bovine serum albumin solution in order to
sensitize it to glucose. Despite the sensor's performance when exposed to H2 0 2 , only
weak and inconsistent responses to glucose were elicited using this procedure. Over the
physiological range of glucose (0 - 20 mM) the maximum response shown by this sensor
was an increase of less than 3 pA (Figure 5.2). The expected response over this range
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Figure 5.2: Sensor response to increasing glucose concentrations. Current readings at
0 mM glucose concentration were considered as background noise and subtracted
from all subsequent values in that trial.
By trying many variations of the fabrication procedure, such as covering the sensor
with Teflon shrink wrap, increasing the applied current, using a higher activity level of
GOx, and making solutions of GOx and 1,3 diaminobenezene, the sensor could be made
to respond to various glucose concentrations. The responses, though, showed no
consistency during subsequent trials with a single needle. These results indicated that
either an insufficient amount of glucose oxidase was immobilized on the needle surface
yielding a weak amperometric response or that the coating was not uniform along the
needle surface. It is also possible that the inner surface area of the hollow needle
influenced the surface area calculations to a greater extent than expected. The procedure
was tried again using a more active strain of the glucose oxidase as well as sealing the
hole in the needle and reducing the total surface area by coating part of the needle with
Teflon. None of the sensors fabricated in this way showed any sensitivity to glucose.
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At this point, alternative methods were sought that would still retain the desired
characteristics of a quick response time, low operating potential, sensor stability,
immunity to chemical interferents, easy fabrication, and potential for miniaturization.
Some of the resulting sensors did respond to glucose, but their responses were again very
small and there was no consistency across trials with each sensor. In some tests, the
sensor response seemed to decrease with subsequent trials, and questions arose as to the
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Figure 5.3: Sensor response to increasing glucose concentrations obtained from a
sensor fabricated using the method of Wang et al. (1992). Current readings at 0 mM
glucose concentration were considered as background noise and subtracted from all
subsequent values in that trial.
One explanation for this decreased response is that excess glucose oxidase was on the
needle surface immediately after fabrication and was then washed away during the trials.
Reliable sensors were eventually fabricated using a method based on one proposed by




5.2 Final Sensor Fabrication Procedure
5.2.1 Materials
Materials used for the final sensor fabrication were nitric acid (see Section 5.2.2
for solution concentrations), hydrochloric acid 37%, rhodium atomic absorption standard
solution, cellulose acetate (39.8 wt. % acetyl content), type VII-S glucose oxidase from
aspergillus niger (E.C. 1.1.3.4, 200,000 units/g), 0.1 M phosphate-buffered saline (PBS)
pH 7.4, glutaric dialdehyde 25 wt. % solution in water, Nafion trimethylsilylated,
hydrogen peroxide 30%, and glucose (Sigma-Aldrich, St. Louis, MO). Silver/silver
chloride (Ag/AgCl) 0.5 mm diameter reference electrodes (part #EPO5, World Precision
Instruments, Inc., Sarasota, FL) were used. All water used to prepare solutions was
deionized. PBS was prepared at least 24 hours in advance to allow for mutarotation.
When glucose is made into solution, it breaks up into cc-D-glucose and p-D-glucose.
Initially, the concentrations of these two types of glucose are not stable. Since the
glucose detection method used detects only P-D-glucose, the glucose solutions were
prepared 48 hours in advance to allow for stability in the P-D-glucose concentration, and
they were replaced every 7 days.
5.2.2 Fabrication Procedure
A 0.51 mm diameter stainless steel wire was cleaned by washing in acetone and
soaking in 110 g/l nitric acid solution for a minimum of 30 minutes. The wire was then
rinsed in stirred distilled water for 4 hours, and finally rinsed in stirred PBS for at least 2
57
hours. After this it was submerged in a 10 ml beaker of 10% HCl for cathodic
pretreatment. A rhodium wire was used as the counter electrode, and a current density of
-50 A/m2 was applied for 2 minutes. Rhodium was galvanostatically deposited onto the
needle surface immediately following the HCl soak by submerging the wire and rhodium
electrode into a 10 ml beaker of stirred 0.35 mM rhodium absorption solution for 3
minutes under a current density of -50 A/m2.
Before any testing was done, the Ag/AgCl electrode was tested for proper
stability. The electrode was shorted to an identical electrode and submerged in 0.1 M
KC1 for approximately 30 minutes, after which both electrodes were rinsed in distilled
water. The two electrodes were submerged in a beaker of PBS and the voltage between
them was recorded. The electrode was considered experimentally viable if the voltage
difference was less than 3 mV.
After testing the Ag/AgCl electrode for stability, the needle was tested for
hydrogen peroxide sensitivity to confirm deposition of rhodium on the needle surface.
The needle was immersed in 16 ml of stirred PBS using the Ag/AgCl electrode as a
counter electrode. A potential of +0.25 V was applied to the needle. Steady state
currents were recorded after every 2 mM addition of H20 2 (3.6 tl increments). An
acceptable rhodium coating would exhibit a rise in current similar to that shown in Figure
5.1 over the biological range of 0-20 mM H202 concentrations.
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After the H202 test, the needle was dipped into a 5% cellulose acetate solution
(CA) in 50% acetone - 50% ethanol for 10 s, exposed to the vapor above the CA for 5 s,
and dipped again into the CA for another 10 s. The CA coated needle was dried in air at
room temperature for approximately 2 minutes. The needle was then placed in a soak of
deionized water for at least 6 hours to permit displacement of entrapped solvent in the
membrane pores. The water in the soak was replaced once during the 6 hour period.
After this, 20 mg of GOx was added to 1 ml of PBS in a plastic container and stirred
gently so as to retain the activity level of the GOx. The needle was dipped into this GOx
solution and allowed to dry for 30 minutes at room temperature while it was held
horizontally. The needle was then placed in a 2% aqueous glutaraldehyde solution for I
hour, after which it was rinsed in deionized water. It was then dried in air for 1 hour
before any testing. The final sensor was stored in phosphate buffered saline at 0' C.
An Ag/AgCl electrode was again used as the reference electrode to determine the
sensor's ability to detect glucose. The sensor and electrode were placed in 20 ml of
stirred PBS, a +0.25 V potential was applied to the sensor, and 2.5 mM increments of
glucose were added. The steady state currents achieved with each glucose addition were
recorded.
A Nafion coating was added to the external surface of the glucose sensor to
enhance sensor sensitivity to glucose by creating a membrane impenetrable to other
chemical interferents and to enhance long-term sensor stability. Solutions of 0.5%, 2.5%,
and 5% were made using 1:1 isopropyl alcohol and deionized water as the solvent. The
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sensor was dipped in the 0.5%, 2.5%, and 5% solutions sequentially, with 15 minutes to
dry at room temperature between each dip. The sensor was then left to dry at room
temperature overnight.
5.3 Experimental Fabrication Results
During the fabrication procedure, the various layers of coatings can be seen
visually on the needle surface. While the initial uncoated wire is silver colored and
shiny, the rhodium coating is a matted black color. The sensor then has a smooth white
surface after the CA and GOx layers have been deposited (Figure 5.4).
Figure 5.4: Sensor surface at various stages of coating. The sensor on
the left has no coatings, the one in the middle is coated with rhodium,
and the one on the right it coated with GOx and CA.
By combining elements of the process described by Bindra et al. (1991) with the
hydrogen peroxide sensor successfully made using the method of Yang et al. (1998),
sensors were formed which showed potential for use as a stable glucose sensor with a
large amperometric response. These glucose sensors displayed a response to increasing
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glucose concentrations in the microamp range with good response consistency over a two
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Figure 5.5: Sensor response to increasing glucose concentrations. Current readings at
0 mM glucose concentration were considered as background noise
and subtracted from all subsequent values in that trial.
A second-order model was fitted to these data using a least squares fit routine:
Day 1: i= O0.001l C2 + 0.0705 C + 0.0742,
Day 2: i = -0.0012 C2 + 0.0728 C + 0.0434,
where i is current in pA and C is concentration in mM. Due to the close similarities of
these two models, it is possible to derive an average model to describe the general
system:
i = -0.00115 C2 + 0.0717 C + 0.0588.
The currents recorded from various sensors showed some variation from sensor to sensor
as indicated in Figure 5.6, although most sensors seem to respond within 10% of the
mean averaged across all fabricated sensors.
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Figure 5.6: Sensor response to increasing glucose concentrations for various
sensors. Current readings at 0 mM glucose concentration were considered
as background noise and subtracted from all subsequent values in that trial.
As expected, after the Nafion coating was deposited on the sensor surface there was a













Figure 5.7: Sensor response to increasing glucose concentrations before and after
application of the Nafion coating. Current readings at 0 mM glucose concentration















Unfortunately the coating did not prolong the lifetime of the sensor as intended. The next
day the sensor showed a very slight and unstable response to increasing glucose
concentrations. Yang et al. (1998) had reported that sensors with Nafion coatings
remained stable for up to 3 months.
5.4 Cyclic Voltammetry Analysis of Sensors
Two of the major interferents to electrochemical glucose sensors are ascorbic acid
and acetaminophen. It would be useful, therefore, to find a way to eliminate the signal
due to these interferents so that an accurate reading of glucose levels can be obtained
even in their presence. Since cyclic voltammograms are specific to each species, it is
possible to use cyclic voltammetry to compare the signals of specific tests and determine
which signals are due to the interferents and which are the desired signals.
Cyclic voltammetry was performed on hydrogen peroxide sensors to determine
whether this method was viable for this application (Figure 5.8).
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Figure 5.8: Diagram of cyclic voltammetry apparatus.
A platinum-iridium wire was used as the counter electrode, and the Ag/AgCl electrode
described above was used as the reference electrode. The input signal was a sine wave
with an amplitude of 0.8 V and a frequency of 1 Hz. Data were sampled at a frequency
of 1000 Hz. The electrodes were placed in a stirred bath of PBS and the concentrations
for H20 2, ascorbic acid, and acetaminophen were increased in separate trials by adding
small amounts of these substances using a pipette in order to simulate concentrations
expected in a human subject (Table 5.1).
Biological Concentrations of Various Species
Species Max. Concentration
H 20 2  20 mM
Ascorbic Acid 100 p.M [Kallner, 1981]
Acetaminophen 2.65 mM [McNeil, 1999]
Table 5.1: Maximum concentrations of H20 2 , ascorbic acid,
and acetaminophen used for cyclic voltammetry tests.
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The results from these tests are shown in Figures 5.9, 5.10, and 5.11.
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Figure 5.11: Voltammogram for increasing concentrations of acetaminophen in a
PBS bath.
A comparison of these three voltammograms indicates that there are clear
differences between them. First, increased concentrations of H202 cause the peaks
around 0.5 V and -0.8 V to change dramatically in amplitude as the central area of the
curve flattens. The magnitude of this change in the peaks is not evident in either of the
other two voltammograms. Secondly, increased concentrations of ascorbic acid do not
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seem to have a large influence on the voltammogram until the concentration has reached
a level well outside the biological range of 100 pM. Even when the voltammogram is
affected by the increased concentration of ascorbic acid, it appears that ascorbic acid
magnifies the entire curve without greatly affecting any particular segment. Finally, the
voltammogram for acetaminophen shows an increase at the peak found at about -0.2 V as
concentration is increased. This increase is not seen in the H20 2 curves at all.
5.5 Conclusions
Using a method for sensor fabrication based on the work of Bindra et al. (1991)
and Yang et al. (1998), needles were consistently sensitized to the addition of glucose.
The variation in the amperometric response from sensor to sensor indicates that a
calibration method will need to be used for each sensor. These sensors showed stability
over at least a 48 hour period. They also retained the desired characteristics of a fast
response time (less than 10 seconds), a low operating potential (+0.25 V), and a process
that can be miniaturized. As such, it appears that this is an appropriate method for sensor
fabrication. Further research is needed to determine an appropriate coating technique for
these sensors to enhance their stability and to block other interferents from the
amperometric response.
The analysis of the voltammograms obtained from the various interferents
indicates that the three substances show very different voltammograms with increased
concentrations. As such, it seems possible to separate out signals from interferents in
order to obtain a pure signal from the H20 2 reaction (and subsequently the response to
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glucose concentration) using such cyclic voltammograms. By doing Fourier transforms
on these data, it may also be possible to fmd peaks which could be used to differentiate
further between the various signals.
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Chapter Six: Micro-needle Array Fabrication
6.1 Justifications for Array Design
The main objective in the glucose sensor design is to create a sensor that measures
glucose levels in such a manner as to eliminate or greatly minimize the pain and
discomfort experienced by the patient. The IF lies directly under the outer layer of skin
above the nerve bundles and reflects the body's glucose levels, as discussed in Chapter 3.
By using a micro-needle to access this fluid without penetrating to the depth of the nerve
endings, glucose measurements can be obtained painlessly.
The epithelial region, however, also contains many large cells. With a single micro-
needle sensor, there is a high probability that the needle will be imbedded in the epithelial
cells rather than the IF. In order to avoid this problem, an array of micro-needles was
designed. In this case, many needles will be in contact with the IF, and a glucose reading
can be taken by summing the signals from the entire array. The array design increases
the sensor surface area (as compared to that of a single micro-needle) that can be
embedded in the IF and thus yields a higher amperometric response.
There are other advantages associated with choosing an array of many micro-needles
over a single "macro-needle." As electrode dimensions decrease, so do the associated
current and double layer thickness, whereas the rate at which chemical species diffuse
towards the electrode increases. This means that microelectrodes respond faster, with
higher signal to noise ratios, less sensitivity to convection, and in more highly resistive
solutions as compared to macroscale electrodes (such as our current single needle
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sensors) [Andrews and Harris, 1998; Wightman, 1988]. Many of these benefits are
amplified when the micro-needle is used in an array format.
6.2 Initial Array Design
Considerable effort has been devoted to developing a low cost method of
manufacturing the micro-needle array. The initial approach consisted of forming a
microhole array in a base plate of Delrin and then placing and securing the micro-needles
into these holes (Figure 6.1).
Figure 6.1: Initial micro-needle array with Delrin baseplate.
Each of the 200 holes has a diameter of 250 pm with a 500 pm center-to-center spacing.
Delrin was chosen for two reasons: 1) its insulating characteristics allow for each needle
to be isolated electrically which will be necessary with a two electrode sensing technique,
and 2) it is a soft material in which small holes can be machined at easily attainable
speeds. Parameters for drilling the holes of this array were based on the work described
by Nielsen (1998).
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Machining of the micro-hole array was done on a computer numeric controlled
(CNC) HAAS machine (model VF-OE). Problems arose in the fabrication of the micro-
hole array due to melting of the Delrin surface and significant burring in the holes, which
would have made needle insertion difficult. Attempts at milling the array surface to
remove the burrs resulted in closing the holes. It was found that much better holes could
be obtained with significantly less burring if a spindle speed of 24,000 rpm was used with
a feed rate of 100 mm/min. A minimum of 250 ptm wall thickness was also specified for
each hole to prevent the holes from joining due to wall melting. The use of a peck
drilling routine helped to eliminate some of the burring (Figures 6.2 and 6.3).
Figure 6.2: Holes with a 250 pm diameter drilled in Delrin. The
hole on the right shows how burring affects the hole opening.
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Figure 6.3: Close up view of a cleared (left) and a burr-filled (right)
250 pm diameter hole.
Standard hypodermic tubing with an outer diameter of 200 ptm was obtained.
Approximately 25 mm length sections of the tubing were tightly packed into a larger tube
and then placed in the wire EDM (Electrostatic Discharge Machining) (Charmilles
Technologies ROBOFIL 1020SI) vice. The wire EDM was used to cut the needles to the
desired length of 3 mm using an angled cut, thereby forming a pointed tip on each needle
for easier penetration of the stratum corneum of the skin (Figure 6.4).
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Figure 6.4: Results of needle cutting using wire EDM
after packing needles in larger tubing.
The EDM machine was used since it imparts almost no force onto the objects it cuts.
This eliminated the potential problem of closing the needle openings during cutting
(Figure 6.5).
Figure 6.5: Close up of needle openings after EDM machining.
Outer diameter of each needle is 200 tm.
The needles were inserted into the baseplate manually and positioned such that
only 50 tm protruded from the array. The needles were then secured in place using
epoxy. This manually constructed array was used to show that a viable array can be
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constructed by combining a baseplate hole array with individual hollow needles (Figure
6.6).
Figure 6.6: Example of a partially filled array with manually inserted needles.
Due to the tedium of manually inserting needles into the array, alternative
insertion methods were investigated. A magnetic shaker system was designed
specifically for the insertion task (Figure 6.7).
Reservoir N
Microhole array
Base and magnet oA
Figure 6.7: Exploded view of magnetic shaker design.
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The needles were placed in a small reservoir positioned directly over the hole array. A
magnet was placed beneath the array in such a manner as to align the needles
perpendicular to the array and to hold the needles in position once they were inserted. A
cap was placed over the reservoir and the entire unit was shaken vigorously until the
needles were inserted (Figure 6.8).
Figure 6.8: Side and top view of actual magnetic shaker.
Although many configurations were tried using this method, only limited success was
achieved. Approximately 80 needles out of 200 were inserted into the array before too
much magnetic interference between the inserted needles and the free needles became an
issue. After insertion, the needles were positioned such that only 50 pm protruded from
the array and fixed in place using epoxy.
6.3 EDM Array Design
Due to some of the problems with the original design of the array, work has also
been done to determine whether the EDM offers a more appropriate method of array
fabrication. Multi-needle arrays have already been fabricated using the EDM, however
these arrays contain solid needles rather than hollow ones. One possibility is to use solid
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needles for the glucose detection (Figure 6.9) and have a hollow needle array used solely
for drug delivery.
Figure 6.9: EDM fabricated micro-needle array.
[Diagram printed with permission of Luke Sosnowski.]
Arrays have been fabricated using stainless steel, tungsten-carbide, and copper,
with as many as ten thousand needles in a single array. These needles have been made
with a base cross-sectional area as small as 100 pim x 100 pm having both uniform cross-
sections and tapered points (Figures 6.10, 6.11).
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Figure 6.10: Micro-needle array formed by microwire EDM.
[Array designed and fabricated by Luke Sosnowski and Tanya Kanigan.]
Figure 6.11: Tapered tips of a micro-needle array formed by EDM.
[Array designed and fabricated by Luke Sosnowski and Tanya Kanigan.]
For the glucose sensor array, an array of tapered needles will be fabricated to facilitate
entry into the skin. Assuming an average needle tip cross-section of 25 pm and
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penetration depth of 50 pm, the sensor surface area per needle is estimated at 5x10-9 m2.
Based upon the 0. 1A/m2 response obtained with the current sensor (after coating with
Nafion), a 10,000 needle array would be necessary to produce an amperometric response
in the microamp range. However, since currents in the nA range are routinely measured,
an array of only 100 needles should produce acceptable signal levels.
The challenge for the glucose sensor array design is that the sensor consists of a
reference and working electrode that must be electrically insulated from one another.
Recent investigations in the Bioinstrumentation lab at MIT have shown that silicon can
be machined using the EDM technology. This leads to the possibility of using passivated
silicon as the array baseplate in order to electrically insulate the working and counter
electrodes. A silicon wafer could be used to fabricate an array of matching through
holes. The surface of this wafer could be thermally oxidized in order to form an
electrically insulating layer, and the resulting oxidized silicon plate could be used as an
insulating sheath between an array of glucose sensors and an array of the Ag/AgCl
reference electrodes. The process of fabricating this device consists of functionalizing
the needles of an EDM array as the working electrodes, inserting this array into a silicon
baseplate predrilled with a matching hole array, and then inserting them through a second













ce Silicon insulating plate needle array
Figure 6.12: Design of EDM fabricated array.
A) Exploded view of individual components.
B) Assembled view of final array.
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These arrays will be attached using an adhesive coating. The insides of the holes in the
glucose sensor array need to be coated with a non-conducting polymer film to prevent
electrical contact between the base of the glucose sensor array and the pins of the
Ag/AgCl reference array (Figure 6.13).
300 pm
Figure 6.13: Cross-section of stainless steel micro-needle
array inserted through a 500 pm thick silicon baseplate.
[Baseplate fabricated by Tanya Kanigan.]
Although many multi-needle arrays have been fabricated with the EDM, they have not
yet been successfully functionalized as glucose sensors. Initial attempts to sensitize a 100
needle array to hydrogen peroxide have been successful, showing an increase in current
with increasing concentrations of hydrogen peroxide over the biological range of 0 - 20
mM (Figure 6.14). These measurements were made by placing the needles of the array
into PBS and adding small increments of hydrogen peroxide through a syringe. The
reference electrode used was Ag/AgCl, and the setup of this experiment was the same as
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Figure 6.14: Array response to hydrogen peroxide.
Due to the increase in surface area provided by the use of an array of micro-needles, the
current response is now in the milliamp range as compared to the microamp range
measured on a single 1.02 mm diameter (18-gauge) needle. Further attempts to sensitize
the arrays to glucose indicated that some modifications to the sensor fabrication
procedure may be necessary. During these attempts, the cellulose acetate tended to
solidify between the micro-needles, thereby closing up the spacing between them. A
more diluted CA solution may solve this problem, or the CA may need to be replaced
entirely.
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Chapter Seven: Future Work
7.1 System Identification Techniques
Most glucose sensor research to date has assumed that a simple statistical correlation
exists between the sensor signal and the glucose concentration. However, the glucose
signal in vivo is greatly affected by the dynamic characteristics of the environment.
Thus, there exists a great need to develop a dynamic model of the mechanisms of glucose
transport in living tissue, which could then be used for predictive measures [Gough and
Armour, 1995]. To accomplish this, system identification techniques could be used to
characterize the glucose response in tissue which would provide vital information to the
field of sensor design. An extensive literature search did identify a few papers in this
area, but all of these studies have been done using mathematical models of the human
glucose response to insulin injections (see Chapter 2). Clearly such analyses should be
performed with actual human glucose response data to determine the human impulse
response to insulin. These analyses would then enable the design of devices for diabetics
that could predict glucose fluctuations as does the normally functioning human pancreas.
One problem with the amperometric needle glucose sensors is that the sensitivity (i.e.,
the magnitude of the current produced for some concentration of glucose) varies
significantly from one sensor to the next, and for a single sensor over time. System ID
techniques can be used as a calibration method for the glucose sensor. By using a
stochastic input of glucose and measuring the sensor's amperometric response, the
impulse response of the sensor can be determined. Such a calibration technique would
allow the sensor to be calibrated easily in vivo.
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In order to show the applicability of system ID techniques to sensor calibration, a
simple setup has been designed that can be used to test the dynamic behavior of glucose
and sensor interaction (Figure 7.1).
Saline
drip
Glucose Sensor Agar gel Glucose injection
Delrin baseplate
Figure 7.1: System ID test setup
A physiological saline solution will be fed via a gravity feed through a slab of agar gel.
The saline will provide a constant flush to the system. The glucose sensor will be
inserted into the far end of the gel, and glucose will be periodically injected at the
opposite end using a micro-stepper-driven syringe. By using standard system
identification techniques to analyze the sensor response, the dynamic response of the
system can be characterized.
A simple version of this setup has been tried using an array sensitive to H20 2.
This was done as a proof of concept showing that the array did respond when H20 2 was
injected into the agar gel. A more complete system needs to be built to provide a
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stochastic input of glucose to the system and thereby measure and characterize the
dynamic response.
7.2 Conclusions
This thesis documents the development of the minimally invasive glucose sensor. A
method has been developed for glucose sensor fabrication, and with minor modifications
to this method, it may be possible to functionalize the outer surface of a micro-needle
array. Various micro-needle arrays have been fabricated by different group members and
positive responses have been achieved when these needles are sensitized to hydrogen
peroxide. It has also been shown that cyclic voltammetry can be a powerful tool in the
signal detection process.
Future work includes the fabrication of a prototype micro-needle array that can
effectively measure glucose levels in IF. Techniques to increase the longevity of the
glucose sensors and appropriate means of fabricating the micro-needle array must be
investigated further. System identification techniques need to be used to identify the
dynamic characteristics of the system as well as to analyze the human insulin response,
which is a vital link in diabetes management. Fourier transform analysis can also be
employed as a powerful tool in further identifying the glucose signal. The sensor and
array designs must be miniaturized in order to create a prototype that can sample IF in a
painless manner.
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By creating a biocompatible glucose sensor, glucose measurements can take place in
vivo, eliminating the need to remove IF from the patient. Further work must be done to
determine the best way to couple this sensor with an automated insulin delivery system.
In this manner, a completely closed-loop system could be designed that would use
measured glucose levels as feedback to the insulin delivery device. This technique could
then be used to maintain optimum glucose levels in the patient throughout the day,
alleviating much of the stress and pain currently endured by diabetics.
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